CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.
Jiazheng LiShaoqing HuangHui ZhuChunhui ShouTianyu LinXiaonan YinQuanjian ZhuDongmei SunXiaoting LiLin ShenJian LiYouwei KouYongjian ZhouBo ZhangHaoran QianJiren YuYe ZhouLei TangXinhua ZhangPublished in: European radiology (2023)
• The RECIST 1.1 criteria outperformed the Choi criteria in identifying progression of GISTs in patients treated with sunitinib. • GISTs displayed different morphologic features on CT depending on how they responded to sunitinib. • Combining CT morphologic features with the RECIST 1.1 criteria allowed for the prompt and accurate identification of progressing GIST lesions.